P013 Driving improvement through audit: impact of 2017 regional audit and survey upon giant cell arteritis services in 2020
Abstract Background/Aims In 2017 an audit and survey of giant-cell arteritis (GCA) services were conducted across northwest England (reported previously). This re-survey in 2020, following publication of revised BSR guidance, sought to identify what changes were made in the intervening period, and...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2021-04, Vol.60 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 60 |
| creator | Sharp, Charlotte A Little, Jayne Shahbaz, Aqsam Wood, E F Wig, Surabhi Watson, Pippa Varughese, Sneha Teh, Lee-Suan Shah, Preeti Saleh, Christopher Ottewell, Lesley Newton, Laura Moore, Sarah R McCarthy, Eoghan MacPhie, Elizabeth Lazarewicz, Karina Brockbank, John Bluett, James Mercer, Louise |
| description | Abstract
Background/Aims
In 2017 an audit and survey of giant-cell arteritis (GCA) services were conducted across northwest England (reported previously). This re-survey in 2020, following publication of revised BSR guidance, sought to identify what changes were made in the intervening period, and provided the opportunity to assess the impact of COVID-19.
Methods
Rheumatologists from 16 hospitals in northwest England were invited to complete a survey in July 2020. Questions focused on service provision for GCA, including pathways, diagnostics and steroid prescription.
Results
Responses were received from 14/16 sites in 2017, and 15/16 in 2020. 9/15 (60%) sites reported that the 2017 audit and survey prompted changes to GCA services, with two (13%) stating that it clarified the need for implementation of existing plans. Two sites had a GCA pathway in 2017. Four of the seven sites who committed to introducing one have now done so, bringing the total in 2020 to six. Eight of the nine remaining sites plan to implement one, six with a specific date within six months. Six (40%) have completed additional local audit/QI since 2017. Temporal artery (TA) ultrasound (US) is now available in an additional four sites, bringing the total to 6/15 (40%) in 2020. Two sites reported improvement in both time between first rheumatology consultation and TA biopsy, and time to receive results (now |
| doi_str_mv | 10.1093/rheumatology/keab247.012 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8135424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/keab247.012</oup_id><sourcerecordid>10.1093/rheumatology/keab247.012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1982-4433a2f706ecd6bf3f51433048a830d942460aca4ce554a7f6550060a1986af93</originalsourceid><addsrcrecordid>eNqNkctKAzEUhgdRsFbfIS_Q9uQyl7oQpF6hoAtdh9NMZhqdmQzJzEAXguCb-iSmtBTduTqH8-f7IPxRRChMKcz5zK11X2NnK1tuZu8aV0ykU6DsKBpRkbAJcM6ODzsTp9GZ928AEFOejaKPZ6D8-_PrxpnBNCUxdevsoGvddKRbO9uXa4J9brrLbYSqI7YgDGhKnC6NbbDaxQSbnPjeDXpD-tY2pDQYFEpX4YHrtDOd8cRrNxilPTFNkDA4j04KrLy-2M9x9Hp3-7J4mCyf7h8X18uJovOMTYTgHFmRQqJVnqwKXsQ0nEBkmHHI54KJBFChUDqOBaZFEscA4RToBIs5H0dXO2_br2qdq_A7h5VsnanRbaRFI_8mjVnL0g4yozwO9iDIdgLlrPdOFweWgtz2IH_3IPc9yNBDQPkOtX37f-oHg8OVqA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P013 Driving improvement through audit: impact of 2017 regional audit and survey upon giant cell arteritis services in 2020</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Sharp, Charlotte A ; Little, Jayne ; Shahbaz, Aqsam ; Wood, E F ; Wig, Surabhi ; Watson, Pippa ; Varughese, Sneha ; Teh, Lee-Suan ; Shah, Preeti ; Saleh, Christopher ; Ottewell, Lesley ; Newton, Laura ; Moore, Sarah R ; McCarthy, Eoghan ; MacPhie, Elizabeth ; Lazarewicz, Karina ; Brockbank, John ; Bluett, James ; Mercer, Louise</creator><creatorcontrib>Sharp, Charlotte A ; Little, Jayne ; Shahbaz, Aqsam ; Wood, E F ; Wig, Surabhi ; Watson, Pippa ; Varughese, Sneha ; Teh, Lee-Suan ; Shah, Preeti ; Saleh, Christopher ; Ottewell, Lesley ; Newton, Laura ; Moore, Sarah R ; McCarthy, Eoghan ; MacPhie, Elizabeth ; Lazarewicz, Karina ; Brockbank, John ; Bluett, James ; Mercer, Louise</creatorcontrib><description>Abstract
Background/Aims
In 2017 an audit and survey of giant-cell arteritis (GCA) services were conducted across northwest England (reported previously). This re-survey in 2020, following publication of revised BSR guidance, sought to identify what changes were made in the intervening period, and provided the opportunity to assess the impact of COVID-19.
Methods
Rheumatologists from 16 hospitals in northwest England were invited to complete a survey in July 2020. Questions focused on service provision for GCA, including pathways, diagnostics and steroid prescription.
Results
Responses were received from 14/16 sites in 2017, and 15/16 in 2020. 9/15 (60%) sites reported that the 2017 audit and survey prompted changes to GCA services, with two (13%) stating that it clarified the need for implementation of existing plans. Two sites had a GCA pathway in 2017. Four of the seven sites who committed to introducing one have now done so, bringing the total in 2020 to six. Eight of the nine remaining sites plan to implement one, six with a specific date within six months. Six (40%) have completed additional local audit/QI since 2017. Temporal artery (TA) ultrasound (US) is now available in an additional four sites, bringing the total to 6/15 (40%) in 2020. Two sites reported improvement in both time between first rheumatology consultation and TA biopsy, and time to receive results (now <7 days for each task in 6/15 (40%)). Six additional sites reported providing leaflets on steroids routinely, bringing the total in 2020 to 12/15 (80%), versus 6/14 (43%) previously. Four sites (27%) now have a database of GCA patients (one in 2017). There was no major change in sites having a standard protocol for steroid taper (n = 8 2017; n = 7 2020, 89% and 100% of whom respectively use BSR guidance), nor in the number of patients routinely provided steroid cards (six in 2017; five in 2020). The three sites who do not report giving leaflets on steroids routinely, all had a pathway. 8/15 (53%) reported COVID-19 having an adverse effect upon services, including: reduced access to diagnostics (n = 7: TA US, biopsy, and PET-CT); delayed appointments (n = 4); delayed referrals (n = 3). The tertiary referral centre reported an improvement because access to tocilizumab was facilitated by a relaxation of rules by NHS England.
Conclusion
The original audit and survey of current GCA practice in 2017 highlighted areas for improvement for each site, and regionally. Sites contributing to this re-survey report that the exercise stimulated them to improve their current care. The 2017 exercise showed a strong correlation between reported practice (survey) and actual practice (audit), leading us to have confidence that responses provided a true picture of care. This work demonstrates the power of audit to drive improvement, at a regional level.
Disclosure
C.A. Sharp: None. J. Little: None. A. Shahbaz: None. E.F. Wood: None. S. Wig: None. P. Watson: None. S. Varughese: None. L. Teh: None. P. Shah: None. C. Saleh: None. L. Ottewell: None. L. Newton: None. S.R. Moore: None. E. McCarthy: Consultancies; E.M. has received consultancy fees from Chugai. E. MacPhie: None. K. Lazarewicz: None. J. Brockbank: None. J. Bluett: None. L. Mercer: None.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keab247.012</identifier><language>eng</language><publisher>Oxford University Press</publisher><subject>Eposters</subject><ispartof>Rheumatology (Oxford, England), 2021-04, Vol.60 (Supplement_1)</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids></links><search><creatorcontrib>Sharp, Charlotte A</creatorcontrib><creatorcontrib>Little, Jayne</creatorcontrib><creatorcontrib>Shahbaz, Aqsam</creatorcontrib><creatorcontrib>Wood, E F</creatorcontrib><creatorcontrib>Wig, Surabhi</creatorcontrib><creatorcontrib>Watson, Pippa</creatorcontrib><creatorcontrib>Varughese, Sneha</creatorcontrib><creatorcontrib>Teh, Lee-Suan</creatorcontrib><creatorcontrib>Shah, Preeti</creatorcontrib><creatorcontrib>Saleh, Christopher</creatorcontrib><creatorcontrib>Ottewell, Lesley</creatorcontrib><creatorcontrib>Newton, Laura</creatorcontrib><creatorcontrib>Moore, Sarah R</creatorcontrib><creatorcontrib>McCarthy, Eoghan</creatorcontrib><creatorcontrib>MacPhie, Elizabeth</creatorcontrib><creatorcontrib>Lazarewicz, Karina</creatorcontrib><creatorcontrib>Brockbank, John</creatorcontrib><creatorcontrib>Bluett, James</creatorcontrib><creatorcontrib>Mercer, Louise</creatorcontrib><title>P013 Driving improvement through audit: impact of 2017 regional audit and survey upon giant cell arteritis services in 2020</title><title>Rheumatology (Oxford, England)</title><description>Abstract
Background/Aims
In 2017 an audit and survey of giant-cell arteritis (GCA) services were conducted across northwest England (reported previously). This re-survey in 2020, following publication of revised BSR guidance, sought to identify what changes were made in the intervening period, and provided the opportunity to assess the impact of COVID-19.
Methods
Rheumatologists from 16 hospitals in northwest England were invited to complete a survey in July 2020. Questions focused on service provision for GCA, including pathways, diagnostics and steroid prescription.
Results
Responses were received from 14/16 sites in 2017, and 15/16 in 2020. 9/15 (60%) sites reported that the 2017 audit and survey prompted changes to GCA services, with two (13%) stating that it clarified the need for implementation of existing plans. Two sites had a GCA pathway in 2017. Four of the seven sites who committed to introducing one have now done so, bringing the total in 2020 to six. Eight of the nine remaining sites plan to implement one, six with a specific date within six months. Six (40%) have completed additional local audit/QI since 2017. Temporal artery (TA) ultrasound (US) is now available in an additional four sites, bringing the total to 6/15 (40%) in 2020. Two sites reported improvement in both time between first rheumatology consultation and TA biopsy, and time to receive results (now <7 days for each task in 6/15 (40%)). Six additional sites reported providing leaflets on steroids routinely, bringing the total in 2020 to 12/15 (80%), versus 6/14 (43%) previously. Four sites (27%) now have a database of GCA patients (one in 2017). There was no major change in sites having a standard protocol for steroid taper (n = 8 2017; n = 7 2020, 89% and 100% of whom respectively use BSR guidance), nor in the number of patients routinely provided steroid cards (six in 2017; five in 2020). The three sites who do not report giving leaflets on steroids routinely, all had a pathway. 8/15 (53%) reported COVID-19 having an adverse effect upon services, including: reduced access to diagnostics (n = 7: TA US, biopsy, and PET-CT); delayed appointments (n = 4); delayed referrals (n = 3). The tertiary referral centre reported an improvement because access to tocilizumab was facilitated by a relaxation of rules by NHS England.
Conclusion
The original audit and survey of current GCA practice in 2017 highlighted areas for improvement for each site, and regionally. Sites contributing to this re-survey report that the exercise stimulated them to improve their current care. The 2017 exercise showed a strong correlation between reported practice (survey) and actual practice (audit), leading us to have confidence that responses provided a true picture of care. This work demonstrates the power of audit to drive improvement, at a regional level.
Disclosure
C.A. Sharp: None. J. Little: None. A. Shahbaz: None. E.F. Wood: None. S. Wig: None. P. Watson: None. S. Varughese: None. L. Teh: None. P. Shah: None. C. Saleh: None. L. Ottewell: None. L. Newton: None. S.R. Moore: None. E. McCarthy: Consultancies; E.M. has received consultancy fees from Chugai. E. MacPhie: None. K. Lazarewicz: None. J. Brockbank: None. J. Bluett: None. L. Mercer: None.</description><subject>Eposters</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkctKAzEUhgdRsFbfIS_Q9uQyl7oQpF6hoAtdh9NMZhqdmQzJzEAXguCb-iSmtBTduTqH8-f7IPxRRChMKcz5zK11X2NnK1tuZu8aV0ykU6DsKBpRkbAJcM6ODzsTp9GZ928AEFOejaKPZ6D8-_PrxpnBNCUxdevsoGvddKRbO9uXa4J9brrLbYSqI7YgDGhKnC6NbbDaxQSbnPjeDXpD-tY2pDQYFEpX4YHrtDOd8cRrNxilPTFNkDA4j04KrLy-2M9x9Hp3-7J4mCyf7h8X18uJovOMTYTgHFmRQqJVnqwKXsQ0nEBkmHHI54KJBFChUDqOBaZFEscA4RToBIs5H0dXO2_br2qdq_A7h5VsnanRbaRFI_8mjVnL0g4yozwO9iDIdgLlrPdOFweWgtz2IH_3IPc9yNBDQPkOtX37f-oHg8OVqA</recordid><startdate>20210426</startdate><enddate>20210426</enddate><creator>Sharp, Charlotte A</creator><creator>Little, Jayne</creator><creator>Shahbaz, Aqsam</creator><creator>Wood, E F</creator><creator>Wig, Surabhi</creator><creator>Watson, Pippa</creator><creator>Varughese, Sneha</creator><creator>Teh, Lee-Suan</creator><creator>Shah, Preeti</creator><creator>Saleh, Christopher</creator><creator>Ottewell, Lesley</creator><creator>Newton, Laura</creator><creator>Moore, Sarah R</creator><creator>McCarthy, Eoghan</creator><creator>MacPhie, Elizabeth</creator><creator>Lazarewicz, Karina</creator><creator>Brockbank, John</creator><creator>Bluett, James</creator><creator>Mercer, Louise</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20210426</creationdate><title>P013 Driving improvement through audit: impact of 2017 regional audit and survey upon giant cell arteritis services in 2020</title><author>Sharp, Charlotte A ; Little, Jayne ; Shahbaz, Aqsam ; Wood, E F ; Wig, Surabhi ; Watson, Pippa ; Varughese, Sneha ; Teh, Lee-Suan ; Shah, Preeti ; Saleh, Christopher ; Ottewell, Lesley ; Newton, Laura ; Moore, Sarah R ; McCarthy, Eoghan ; MacPhie, Elizabeth ; Lazarewicz, Karina ; Brockbank, John ; Bluett, James ; Mercer, Louise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1982-4433a2f706ecd6bf3f51433048a830d942460aca4ce554a7f6550060a1986af93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Eposters</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharp, Charlotte A</creatorcontrib><creatorcontrib>Little, Jayne</creatorcontrib><creatorcontrib>Shahbaz, Aqsam</creatorcontrib><creatorcontrib>Wood, E F</creatorcontrib><creatorcontrib>Wig, Surabhi</creatorcontrib><creatorcontrib>Watson, Pippa</creatorcontrib><creatorcontrib>Varughese, Sneha</creatorcontrib><creatorcontrib>Teh, Lee-Suan</creatorcontrib><creatorcontrib>Shah, Preeti</creatorcontrib><creatorcontrib>Saleh, Christopher</creatorcontrib><creatorcontrib>Ottewell, Lesley</creatorcontrib><creatorcontrib>Newton, Laura</creatorcontrib><creatorcontrib>Moore, Sarah R</creatorcontrib><creatorcontrib>McCarthy, Eoghan</creatorcontrib><creatorcontrib>MacPhie, Elizabeth</creatorcontrib><creatorcontrib>Lazarewicz, Karina</creatorcontrib><creatorcontrib>Brockbank, John</creatorcontrib><creatorcontrib>Bluett, James</creatorcontrib><creatorcontrib>Mercer, Louise</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharp, Charlotte A</au><au>Little, Jayne</au><au>Shahbaz, Aqsam</au><au>Wood, E F</au><au>Wig, Surabhi</au><au>Watson, Pippa</au><au>Varughese, Sneha</au><au>Teh, Lee-Suan</au><au>Shah, Preeti</au><au>Saleh, Christopher</au><au>Ottewell, Lesley</au><au>Newton, Laura</au><au>Moore, Sarah R</au><au>McCarthy, Eoghan</au><au>MacPhie, Elizabeth</au><au>Lazarewicz, Karina</au><au>Brockbank, John</au><au>Bluett, James</au><au>Mercer, Louise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P013 Driving improvement through audit: impact of 2017 regional audit and survey upon giant cell arteritis services in 2020</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><date>2021-04-26</date><risdate>2021</risdate><volume>60</volume><issue>Supplement_1</issue><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>Abstract
Background/Aims
In 2017 an audit and survey of giant-cell arteritis (GCA) services were conducted across northwest England (reported previously). This re-survey in 2020, following publication of revised BSR guidance, sought to identify what changes were made in the intervening period, and provided the opportunity to assess the impact of COVID-19.
Methods
Rheumatologists from 16 hospitals in northwest England were invited to complete a survey in July 2020. Questions focused on service provision for GCA, including pathways, diagnostics and steroid prescription.
Results
Responses were received from 14/16 sites in 2017, and 15/16 in 2020. 9/15 (60%) sites reported that the 2017 audit and survey prompted changes to GCA services, with two (13%) stating that it clarified the need for implementation of existing plans. Two sites had a GCA pathway in 2017. Four of the seven sites who committed to introducing one have now done so, bringing the total in 2020 to six. Eight of the nine remaining sites plan to implement one, six with a specific date within six months. Six (40%) have completed additional local audit/QI since 2017. Temporal artery (TA) ultrasound (US) is now available in an additional four sites, bringing the total to 6/15 (40%) in 2020. Two sites reported improvement in both time between first rheumatology consultation and TA biopsy, and time to receive results (now <7 days for each task in 6/15 (40%)). Six additional sites reported providing leaflets on steroids routinely, bringing the total in 2020 to 12/15 (80%), versus 6/14 (43%) previously. Four sites (27%) now have a database of GCA patients (one in 2017). There was no major change in sites having a standard protocol for steroid taper (n = 8 2017; n = 7 2020, 89% and 100% of whom respectively use BSR guidance), nor in the number of patients routinely provided steroid cards (six in 2017; five in 2020). The three sites who do not report giving leaflets on steroids routinely, all had a pathway. 8/15 (53%) reported COVID-19 having an adverse effect upon services, including: reduced access to diagnostics (n = 7: TA US, biopsy, and PET-CT); delayed appointments (n = 4); delayed referrals (n = 3). The tertiary referral centre reported an improvement because access to tocilizumab was facilitated by a relaxation of rules by NHS England.
Conclusion
The original audit and survey of current GCA practice in 2017 highlighted areas for improvement for each site, and regionally. Sites contributing to this re-survey report that the exercise stimulated them to improve their current care. The 2017 exercise showed a strong correlation between reported practice (survey) and actual practice (audit), leading us to have confidence that responses provided a true picture of care. This work demonstrates the power of audit to drive improvement, at a regional level.
Disclosure
C.A. Sharp: None. J. Little: None. A. Shahbaz: None. E.F. Wood: None. S. Wig: None. P. Watson: None. S. Varughese: None. L. Teh: None. P. Shah: None. C. Saleh: None. L. Ottewell: None. L. Newton: None. S.R. Moore: None. E. McCarthy: Consultancies; E.M. has received consultancy fees from Chugai. E. MacPhie: None. K. Lazarewicz: None. J. Brockbank: None. J. Bluett: None. L. Mercer: None.</abstract><pub>Oxford University Press</pub><doi>10.1093/rheumatology/keab247.012</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2021-04, Vol.60 (Supplement_1) |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8135424 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Eposters |
| title | P013 Driving improvement through audit: impact of 2017 regional audit and survey upon giant cell arteritis services in 2020 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T22%3A30%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P013%E2%80%83Driving%20improvement%20through%20audit:%20impact%20of%202017%20regional%20audit%20and%20survey%20upon%20giant%20cell%20arteritis%20services%20in%202020&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Sharp,%20Charlotte%20A&rft.date=2021-04-26&rft.volume=60&rft.issue=Supplement_1&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keab247.012&rft_dat=%3Coup_pubme%3E10.1093/rheumatology/keab247.012%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/rheumatology/keab247.012&rfr_iscdi=true |